Drug safety evaluation of roflumilast for the treatment of COPD: a meta-analysis
The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
INTRODUCTION: Roflumilast is the only phosphodiesterase 4 inhibitor approved for the treatment of COPD patients with chronic cough and sputum, and a history of exacerbations, but the compliance to treatment is reduced by poorly tolerated adverse events (AEs). AREAS COVERED: The synthesis of clinical evidences indicates that roflumilast 500μg once-daily increased the risk of AEs, with no impact on the risk of serious AEs (SAEs), compared with placebo. Gastrointestinal AEs were common in patients treated with roflumilast, that may also induce headache, backpain and insomnia. Roflumilast protects against COPD related AEs. The frequency of very SAEs was rare but greater in patients treated with roflumilast than placebo, although factors other than the study drug were related with these SAEs. EXPERT OPINION: The safety profile of roflumilast administered in combination with further drugs for the treatment of COPD should be investigated through specifically designed RCTs, and the post-marketing surveillance might help to characterize the real risk of very SAEs. Roflumilast may provide more benefit than harm in patients at high risk of severe exacerbations, and the therapy discontinuation may be reduced by a correct education of patients on the generally transient and mild-to-moderate nature of gastrointestinal AEs induced by this drug.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Funnel plots for detecting bias in meta-analysis
Sterne, J. A. C., & Egger, M. (2001) · Journal of Clinical Epidemiology · doi:10.1016/s0895-4356(01)00377-8 · Cited by 3,779
GRADE guidelines 6. Rating the quality of evidence—imprecision
Guyatt, G. H., Oxman, A. D., Kunz, R., Brozek, J., Alonso-Coello, P., Rind, D., Devereaux, P. J., Montori, V. M., Freyschuss, B., Vist, G., et al. (2011) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2011.01.012 · Cited by 2,693 · cited 1×
“05) moderate to high levels of heterogeneity were considered for I(2) > 50% [37], and the optimal information size (OIS) was assessed as previously reported [38,39].”
MethodPublication and related bias in meta-analysis
Sterne, J. A. C., Gavaghan, D., & Egger, M. (2000) · Journal of Clinical Epidemiology · doi:10.1016/s0895-4356(00)00242-0 · Cited by 2,282
Astrup, A., Rössner, S., Van Gaal, L., Rissanen, A., Niskanen, L., Al Hakim, M., Madsen, J., Rasmussen, M. F., & Lean, M. E. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61375-1 · Cited by 1,163
Closing the Gap between Methodologists and End-Users: R as a Computational Back-End
Wallace, B. C., Dahabreh, I. J., Trikalinos, T. A., Lau, J., Trow, P., & Schmid, C. H. (2012) · Journal of Statistical Software · doi:10.18637/jss.v049.i05 · Cited by 1,125
Robichaud, A., Stamatiou, P. B., Jin, S.-L. C., Lachance, N., MacDonald, D., Laliberté, F., Liu, S., Huang, Z., Conti, M., & Chan, C.-C. (2002) · Journal of Clinical Investigation · doi:10.1172/jci15506 · Cited by 267
Meta-analysis of rare and adverse event data
Sutton, A. J., Cooper, N. J., Lambert, P. C., Jones, D. R., Abrams, K. R., & Sweeting, M. J. (2002) · Expert Review of Pharmacoeconomics & Outcomes Research · doi:10.1586/14737167.2.4.367 · Cited by 141
Cited by
Phosphodiesterase-4 Inhibitors for the Treatment of Inflammatory Diseases
Li, H., Zuo, J., & Tang, W. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.01048 · Cited by 580
“In view of the relative balance between efficacy and safety, roflumilast indeed provides much more benefit than harm in patients, according to drug safety evaluation of medication under a correct education and administration strategy (Rogliani et al., 2016).”
BackgroundRoflumilast: A potential drug for the treatment of cognitive impairment?
Sugin, L. J. S., Murugesan, A., Bindu, M., & Sunil, K. N. (2020) · Neuroscience Letters · doi:10.1016/j.neulet.2020.135281 · Cited by 24
Muo, I. M., MacDonald, S. D., Madan, R., Park, S.-J., Gharib, A. M., Martinez, P. E., Walter, M. F., Yang, S. B., Rodante, J. A., Courville, A. B., et al. (2019) · Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy · doi:10.2147/dmso.s182953 · Cited by 21
Metadata
- Authors
- Rogliani, P., Calzetta, L., Cazzola, M., & Matera, M. G.
- Venue
- Expert Opinion on Drug Safety
- Publisher
- Informa UK Limited
- Published
- 2016-06-20
- Volume
- 15
- Issue
- 8
- Pages
- 1133-1146
- ISSN
- 1474-0338 (ISSN-L)
- 1744-764X
- OpenAlex
- W2413517616
- Cited by
- 66
- References
- 7
- FWCI
- 1.98
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Drug safety evaluation of roflumilast for the treatment of COPD: a meta-analysis. https://app.cochat.ai/papers/10.1080/14740338.2016.1199683
- The paper
- Rogliani, P., Calzetta, L., Cazzola, M., & Matera, M. G. (2016). Drug safety evaluation of roflumilast for the treatment of COPD: a meta-analysis. Expert Opinion on Drug Safety. https://doi.org/10.1080/14740338.2016.1199683
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.